Stock Track | CorMedix Soars 5.20% Pre-Market on Strong Q1 Earnings Beat and Positive Outlook

Stock Track

May 06, 2025

CorMedix Inc. (NASDAQ: CRMD) saw its stock price surge 5.20% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results, which significantly exceeded analyst expectations.

The biopharmaceutical company reported earnings per share (EPS) of $0.30, surpassing the consensus estimate of $0.24 by 25%. This marks a substantial improvement from the $0.25 loss per share reported in the same quarter last year. CorMedix's revenue also impressed, coming in at $39.08 million, beating analyst projections of $36 million by 8.55%.

Investors were further encouraged by CorMedix's strong cash position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Additionally, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half sales guidance range of $62 million to $70 million. This positive financial performance and forward-looking statement likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1112853113"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112853113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112853113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-06 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112853113","market":"nz","top_or_hot":-1,"title":"Stock Track | CorMedix Soars 5.20% Pre-Market on Strong Q1 Earnings Beat and Positive Outlook","media":"Stock Track","content":"<p>CorMedix Inc. (NASDAQ: CRMD) saw its stock price surge 5.20% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results, which significantly exceeded analyst expectations.</p>\n\n<p>The biopharmaceutical company reported earnings per share (EPS) of $0.30, surpassing the consensus estimate of $0.24 by 25%. This marks a substantial improvement from the $0.25 loss per share reported in the same quarter last year. CorMedix's revenue also impressed, coming in at $39.08 million, beating analyst projections of $36 million by 8.55%.</p>\n\n<p>Investors were further encouraged by CorMedix's strong cash position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Additionally, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half sales guidance range of $62 million to $70 million. This positive financial performance and forward-looking statement likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CorMedix Soars 5.20% Pre-Market on Strong Q1 Earnings Beat and Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CorMedix Soars 5.20% Pre-Market on Strong Q1 Earnings Beat and Positive Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-06 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CorMedix Inc. (NASDAQ: CRMD) saw its stock price surge 5.20% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results, which significantly exceeded analyst expectations.</p>\n\n<p>The biopharmaceutical company reported earnings per share (EPS) of $0.30, surpassing the consensus estimate of $0.24 by 25%. This marks a substantial improvement from the $0.25 loss per share reported in the same quarter last year. CorMedix's revenue also impressed, coming in at $39.08 million, beating analyst projections of $36 million by 8.55%.</p>\n\n<p>Investors were further encouraged by CorMedix's strong cash position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Additionally, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half sales guidance range of $62 million to $70 million. This positive financial performance and forward-looking statement likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1112853113","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112853113","pubTimestamp":1746532992,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CorMedix Inc.  saw its stock price surge 5.20% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results, which significantly exceeded analyst expectations.The biopharmaceutical company reported earnings per share  of $0.30, surpassing the consensus estimate of $0.24 by 25%. This marks a substantial improvement from the $0.25 loss per share reported in the same quarter last year. CorMedix's revenue also impressed, coming in at $39.08 million, beating anal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"由于第一季度盈利强劲且前景乐观，CorMedix盘前飙升5.20%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"CorMedix Inc. (NASDAQ: CRMD) saw its stock price surge 5.20% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results, which significantly exceeded analyst expectations.\nThe biopharmaceutical company reported earnings per share (EPS) of $0.30, surpassing the consensus estimate of $0.24 by 25%. This marks a substantial improvement from the $0.25 loss per share reported in the same quarter last year. CorMedix's revenue also impressed, coming in at $39.08 million, beating analyst projections of $36 million by 8.55%.\nInvestors were further encouraged by CorMedix's strong cash position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Additionally, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half sales guidance range of $62 million to $70 million. This positive financial performance and forward-looking statement likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}